This study reports the experience of treating 10 patients with recurrent malignant gliomas located in deep areas or functionally relevant structures of the brain using sPDT; here, patients without the IDH1/2 gene mutation predominated (7 out of 9 examined). This evidence concerns the gene IDH1 and malignant glioma.